Back to library
MetabolicOral
Tesofensine
Also known as: NS2330
Triple monoamine reuptake inhibitor (dopamine, noradrenaline, serotonin). Originally developed for Parkinson's and Alzheimer's; weight-loss effects emerged as adverse-event findings. Suppresses appetite via central noradrenergic and dopaminergic signaling.
At a glance
- Half-life
- 9.8 days
- Common route
- Oral
- Typical dose range
- 250–1,000mcg
- Stability (reconstituted)
- 90days refrigerated
Best timing
Once daily in the morning. Long half-life means steady-state takes ~5 weeks to reach.
Contraindications
- Cardiovascular disease, arrhythmia, or uncontrolled hypertension
- Concurrent MAOI use
- History of substance use disorder
- Pregnancy
- Hyperthyroidism
Watch symptoms
- Resting heart rate and blood pressure elevation
- Insomnia, anxiety, agitation
- Dry mouth, constipation
- Mood changes — euphoria or dysphoria
- Risk of dependence at higher doses
Citations